Routine evaluation of prostate size not as effective in cancer screening, Mayo study finds
New Mayo Clinic research studied the association between prostate-specific antigen (PSA) levels and prostate size and found that routine annual evaluation of prostate growth is not necessarily a predictor for the development of prostate cancer. However the study suggests that if a man’s PSA level is rising quickly, a prostate biopsy is reasonable to determine if he has prostate cancer. These findings are being presented this week at the North Central Section of the American Urological Association (http://www.ncsaua.org/) in Scottsdale, Ariz.
VIDEO ALERT: Additional audio and video resources are available on the Mayo Clinic News Blog (http://newsblog.mayoclinic.org/2009/11/09/routine-prostate-size-evaluation-not-as-effective-in-cancer-screening/).
These Mayo Clinic study findings were based on data in the Olmsted County Study of Urinary Health Status among Men, a large cohort study of men living in Olmsted County, Minn. Researchers randomly selected 616 men between the ages of 40 and 79 who did not have prostate disease. Patients participated in examinations every two years for 17 years, which included PSA and prostate volume measurements using ultrasound, to determine changes in prostate disease.
“One of the major advantages of this large cohort study is that the men have participated in this study for over 17 years,” says Rodney Breau, M.D., a Mayo Clinic urologic oncology fellow who led the study. Because of this, we have the ability to look at long-term relationships between prostate growth, change in PSA and development of prostate cancer.”
Of the 616 men, 58 (9.4 percent) developed prostate cancer. Men who were diagnosed with prostate cancer had a faster rise in PSA levels (6 percent/year) compared to men who were not diagnosed with cancer (3.3 percent/year). However, the increase in prostate size was similar between these two groups (median change of 2.2 percent/year).
PSA is a substance produced in the prostate gland. Normally, a small amount of PSA enters the bloodstream. A higher amount of PSA or an abrupt rise in PSA levels can indicate a problem, possibly cancer.
“The question we’re trying to answer is, if we see a man with a rising PSA level, could this change in PSA be explained by a proportional increase in prostate size?” says Dr. Breau. “Our data indicate that men with or without prostate cancer have similar rates of prostate growth. If a man’s PSA is quickly rising, he likely deserves a prostate biopsy to determine if he has prostate cancer. Assessment of change in prostate size should not influence the decision to biopsy.”
Other Mayo Clinic researchers involved in this study include: R. Jeffrey Karnes, M.D. (http://www.mayoclinic.org/bio/12463493.html); Debra Jacobson; Michaela McGree; Steven Jacobsen, M.D., Ph.D.; Ajay Nehra, M.D. (http://www.mayoclinic.org/bio/12370606.html); Michael Lieber, M.D. (http://www.mayoclinic.org/bio/10203567.html); and Jennifer St. Sauver, Ph.D.
About Mayo Clinic
Mayo Clinic is the first and largest integrated, not-for-profit group practice in the world. Doctors from every medical specialty work together to care for patients, joined by common systems and a philosophy of “the needs of the patient come first.” More than 3,700 physicians, scientists and researchers and 50,100 allied health staff work at Mayo Clinic, which has sites in Rochester, Minn; Jacksonville, Fla; and Scottsdale/Phoenix, Ariz. Collectively, the three locations treat more than half a million people each year. To obtain the latest news releases from Mayo Clinic, go to http://www.mayoclinic.org/news. For information about research and education, visit http://www.mayo.edu. MayoClinic.com (http://www.mayoclinic.com) is available as a resource for your health stories.
Contact: Amy Tieder
Tell-a-Friend comments powered by Disqus